CartiHeal Raises $15M For Its Bone Regeneration Implant

January 12, 2016 | Israeli medical device company CartiHeal has raised $15 million in a round of financing led by Johnson & Johnson Innovation. Existing investors Elron Electronic Industries, Accelmed, Access Medical Ventures and Peregrine Ventures, also participated. The new funds will be used to scale-up manufacturing  of its primary product, the Agili-C implant, which has “demonstrated outstanding ability to reproducibly regenerate hyaline cartilage,” according to Founder & CEO Nir Altschuler. Especially pertinent to osteoarthritis, Agili-C enables biological resurfacing of cartilage and its underlying subchondral bone through a tissue regeneration process. The implant has been successfully implanted in nearly 200 patients throughout Europe, and after obtaining CE approval, the company is preparing for initial European commercialization in 2017.